BioMarin stock gets fresh five-year Pompe data signal

Published on 10/05/2026 at 21:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioMarin stock traded at USD 57.55 on October 5, 2026, with a USD 11.1 billion market value. Q2 revenue reached USD 989.71 million, up 20 percent year over year.

BMRN, US09061G1013, Illustration mit AI erstellt.

BioMarin stock (ISIN US09061G1013) traded at USD 57.55 on Nasdaq at 3:56 p.m. ET on October 5, 2026, up USD 0.37, or 0.65 percent, from the prior close of USD 57.18. The latest company event is a five-year clinical update for POMBILITI and OPFOLDA in late-onset Pompe disease, presented on October 2, 2026.

Five-year Pompe data add depth

According to BioMarin on October 2, 2026, the PROPEL open-label extension followed 82 people who continued the treatment from baseline through year five. In the ERT-experienced group, the mean change in predicted six-minute walk distance was 0.7 percent, while predicted forced vital capacity changed by minus 2.8 percent.

The safety profile also carries a measurable counterweight. BioMarin reported treatment-related adverse events in 51.2 percent of participants, with five people discontinuing treatment for safety reasons.

Revenue beat supports the pipeline

BioMarin's second-quarter 2026 revenue reached USD 989.71 million, up 20 percent from the prior-year quarter, according to MarketBeat in its October 1, 2026 report. Adjusted EPS was USD 1.20 against a USD 0.95 consensus, while revenue exceeded the USD 932.03 million estimate.

The company website identifies Q2 2026 as its latest quarterly reporting period, and the results include the commercial portfolio and pipeline that underpin the 2026 outlook. That combination makes the Pompe data relevant beyond one study because it adds a longer clinical readout to a business already producing double-digit quarterly growth.

Analyst target stays above the quote

MarketBeat lists a Moderate Buy consensus from 24 analysts, with 15 buy ratings, seven holds, one sell and one strong buy. Its average 12-month target of USD 89.17 lies 55.0 percent above the USD 57.55 Nasdaq price on October 5, 2026.

Analyst views remain differentiated. Investing.com reported on September 16, 2026 that BMO Capital lowered its target from USD 98 to USD 97 while maintaining an Outperform rating. The change followed BioMarin's decision to discontinue VOXZOGO development for children with Noonan syndrome.

BioMarin stock trades below its yearly high

At USD 57.55 on October 5, 2026, BioMarin stock stood within its USD 49.26 to USD 70.98 52-week range. The company carried a market capitalization of USD 11.1 billion, making the valuation gap to the analyst average a central market measure alongside the new clinical evidence.